Zacks Investment Research Upgrades CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) to Buy

Zacks Investment Research upgraded shares of CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) from a hold rating to a buy rating in a research report report published on Thursday, reports. They currently have $2.75 price target on the biotechnology company’s stock.

According to Zacks, “Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company’s lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. “

NYSEAMERICAN CANF opened at $2.34 on Thursday. CAN-FITE BIOPHA/S has a 1-year low of $2.14 and a 1-year high of $25.95.

A hedge fund recently raised its stake in CAN-FITE BIOPHA/S stock. Meitav Dash Investments Ltd. lifted its stake in shares of CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) by 8.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 508,630 shares of the biotechnology company’s stock after buying an additional 39,500 shares during the quarter. Meitav Dash Investments Ltd. owned approximately 2.55% of CAN-FITE BIOPHA/S worth $448,000 at the end of the most recent reporting period. 5.12% of the stock is owned by institutional investors.


Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Featured Article: Trading Ex-Dividend

Get a free copy of the Zacks research report on CAN-FITE BIOPHA/S (CANF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with's FREE daily email newsletter.